1. Home
  2. TRIB vs CMMB Comparison

TRIB vs CMMB Comparison

Compare TRIB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRIB

Trinity Biotech plc

HOLD

Current Price

$0.62

Market Cap

14.0M

Sector

Health Care

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.68

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIB
CMMB
Founded
1992
2004
Country
Ireland
Israel
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.0M
11.2M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
TRIB
CMMB
Price
$0.62
$1.68
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
236.8K
45.6K
Earning Date
03-23-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
$13.51
N/A
Revenue Next Year
$13.14
N/A
P/E Ratio
N/A
$42.00
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.87
52 Week High
$3.44
$3.86

Technical Indicators

Market Signals
Indicator
TRIB
CMMB
Relative Strength Index (RSI) 43.43 49.87
Support Level $0.50 $1.47
Resistance Level $0.80 $1.85
Average True Range (ATR) 0.06 0.16
MACD 0.00 -0.00
Stochastic Oscillator 48.61 38.71

Price Performance

Historical Comparison
TRIB
CMMB

About TRIB Trinity Biotech plc

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: